KR20220163542A - Composition for anti-oxidation, anti-inflammation, and anti-pollution containing an extraction of Backhousia citriodora and Sparassis crispa - Google Patents

Abstract

The present invention relates to a composition for anti-oxidation, anti-inflammation, and anti-pollution containing a mixed extract of Backhousia citriodora and Sparassis crispa, wherein the mixed extract of Backhousia citriodora and Sparassis crispa has excellent DPPH radical scavenging activity and lipid peroxidation inhibitory effect, effectively inhibits inflammation, and has excellent anti-inflammatory effect as well. Therefore, the mixed extract of Backhousia citriodora and Sparassis crispa can be used in medicine, food, cosmetics, etc. for antioxidant and/or anti-inflammatory purposes. In addition, the mixed extract of Backhousia citriodora and Sparassis crispa can be used as an anti-pollution material by utilizing antioxidant and anti-inflammatory effects.

Description

Composition for anti-oxidation, anti-inflammation, and anti-pollution containing an extraction of Backhousia citriodora and Sparassis crispa}

The present invention relates to a composition for antioxidant, anti-inflammatory and anti-pollution comprising a mixed extract of lemon myrtle and zinnia mushroom.

Fine dust collectively refers to dust with a particle size of 10㎛ or less, abbreviated as PM ₁₀ (Particulate Matter 10), and is classified as PM _2.5 (Particulate Matter 2.5), which is ultra-fine dust with a particle size of 2.5㎛ or less. It is mainly generated when fossil fuels are burned, and fine dust from China, which relies on coal for 70%, accounts for a large part. In addition, yellow dust refers to a phenomenon in which small sand, ocher, or dust from deserts and loess regions in the center of the Asian continent, such as China and Mongolia, floats in the sky and is blown away by the wind from the upper layers. this is possible

In particular, when fine dust comes in direct contact with the skin, which is located on the outermost part of our body, the skin acts as a barrier function between the organism and the environment. cause problems In particular, since fine dust is 20 times smaller than pores, it can easily penetrate the human skin. For example, in the skin, which is a major site for absorbing environmental pollutants, absorption of a toxic substance such as chloroform through the skin is considered equivalent to inhalation through the respiratory tract.

Fine dust causes oxidative stress and inflammation in the body or skin. The induced inflammation affects the whole body and increases the risk of skin inflammatory diseases, hair loss, atopic aggravation, stroke, brain inflammatory diseases such as Alzheimer's disease, respiratory diseases, and cardiovascular diseases.

Currently, the demand for anti-inflammatory and antioxidant functional materials that protect against inflammatory reactions and oxidative stress caused by stimuli such as fine dust is rapidly increasing. A small number of new materials are needed.

Republic of Korea Patent No. 10-1851603

An object to be solved by the present invention is to provide an antioxidant or anti-inflammatory composition comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient, and the composition includes a food composition, a cosmetic composition, a pharmaceutical composition, and a quasi-drug composition.

Another object of the present invention is to provide a cosmetic composition for anti-pollution comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

One embodiment of the present invention is an antioxidant or anti-inflammatory food composition comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

The mixed extract may be extracted by mixing lemon myrtle and zinnia mushroom in a weight ratio of 1:0.1 to 10.

The mixed extract may be a hot water extract of lemon myrtle and zinnia mushroom.

Another embodiment of the present invention is an antioxidant or anti-inflammatory cosmetic composition comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

Another embodiment of the present invention is a pharmaceutical composition for preventing or treating inflammatory diseases comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

The inflammatory disease may be a brain or neuroinflammatory disease.

Another embodiment of the present invention is a quasi-drug composition for antioxidant or anti-inflammatory comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

Another embodiment of the present invention is a cosmetic composition for anti-pollution comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

The anti-pollution may be to suppress inflammation or oxidative stress induced by yellow dust or fine dust.

The present invention relates to an antioxidant or anti-inflammatory composition comprising a mixed extract of lemon myrtle and zinnia mushroom. The mixed extract of lemon myrtle and zinnia mushroom has excellent DPPH radical scavenging activity and lipid peroxidation inhibitory effect, and it has been confirmed that it effectively inhibits inflammation, so it can be used for antioxidant or anti-inflammatory purposes.

In addition, the mixed extract of lemon myrtle and zinnia mushroom can be used to develop an anti-pollution cosmetic that relieves oxidative stress and inflammation caused by fine dust.

Hereinafter, specific embodiments of the present invention will be described in more detail so that those skilled in the art can easily implement the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.

In one aspect, the present invention relates to an antioxidant or anti-inflammatory food composition comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

The antioxidant or anti-inflammatory food composition of the present invention includes a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

In the present invention, “lemon myrtle ( Backhousia citriodora )” is a shrub native to the tropical forests of Queensland, Australia. The leaves of the lemon myrtle have a lemon scent, and are the most widely used spices in Australia. In addition, the lemon myrtle-derived oil has the strongest and longest-lasting scent among several lemon-scented oils, and is often used when making soap, lip balm, or perfume. The lemon flavor of the lemon myrtle is due to the citral component, and unlike lemon, which contains about 3 to 10% of lemon, about 90% is included, so it has a stronger lemon flavor or aroma than lemon, As a result, it is reported to have a strong astringent and bitter taste. The citral is a monoterpene-based aldehyde component and is known to be insoluble in water but mainly soluble in alcohol or ether.

In the present invention, "crisp mushroom ( Sparassis crispa )" is a mushroom belonging to the mushroom mushroom family ( Aphyllophorales ) and the flower mushroom family ( Sparassidaceae ), and is distributed in Korea, Japan, China, Europe, North America, Australia, etc., August-September It grows wild near the roots of coniferous trees or on stumps. The fruit body is 10-25 cm high, fleshy, the lower part is a thick stem with a common stalk, the upper part is flat, and the edge is wavy, forming a white cauliflower shape. . In addition, the content of β-1,3-D-glucan is much higher than that of other mushrooms, and it is known to have various physiological activity effects. That is, it is known to be effective against anti-cancer and anti-angiogenic effects, anti-tumor effects, antibacterial and antifungal effects, and anti-allergic effects and diabetes. It is also involved in the production of cytokines in mice and is effective against acute liver damage.

In the present invention, "extract" refers to an extract obtained by extraction treatment, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof, etc. It includes extracts of all formulations that can be formed by

In the present invention, the extract may be processed by a known method to the extent that useful components are not destroyed from dried plants, for example, by natural drying in the shade. In addition, crushing or pulverization may be pulverized by crushing or pulverizing to the extent that useful components of the plant can be sufficiently extracted in the subsequent extraction process. The drying and crushing or crushing process may be carried out in reverse order or repeatedly if necessary.

The extract may be prepared according to a conventional plant extract manufacturing method, and specifically, may be a solvent extraction method, water immersion extraction method, cold needle extraction method, warm needle extraction method, or ultrasonic extraction method. available.

The extraction solvent of the extract may be water or an organic solvent. The organic solvent may be a polar solvent, a non-polar solvent, or a mixture thereof, and may be, for example, alcohol, alcohol dilution water, hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, or a mixture thereof, and the alcohol may be a C ₁ to C ₅ alcohol, for example methanol, ethanol, propanol, butanol, isopropanol, and the like. In addition, the alcohol dilution water may be diluted with water to 50 to 99.9% (v / v) of alcohol.

In addition, the extract extracted with the solvent may be further subjected to a fractionation process with any one solvent selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water, and mixtures thereof. At the time of the fractionation, two or more solvents may be used, and each solvent fraction may be prepared by sequentially using or mixing according to the polarity of the solvent.

The prepared extract or the fraction obtained by performing the fractionation process may then be filtered or concentrated or dried to remove the solvent, and filtration, concentration, and drying may all be performed. Specifically, the filtration may be performed using a filter paper or a vacuum filter, the concentration may be concentrated under reduced pressure using a vacuum concentrator, for example, a rotary evaporator, and the drying may be performed, for example, by a lyophilization method.

In the present invention, "mixed extract" may be an extract prepared by extracting lemon myrtle and zinnia mushroom, prepared by extracting and mixing lemon myrtle and zinnia mushroom, or by mixing lemon myrtle and zinnia mushroom and then extracting. have.

The lemon myrtle may be at least one selected from the group consisting of stems, leaves, roots, flowers, and fruits, and preferably may be lemon myrtle leaves.

After mixing dried lemon myrtle and zinnia mushroom in one embodiment of the present invention, distilled water was mixed and extracted for 1 to 5 hours using a pressurized extract at 80 to 120 ° C. as a solvent.

Therefore, the mixed extract of the present invention may be hot water extraction of lemon myrtle and zinnia mushroom, specifically hot water extraction at 90 to 110 ° C. for 2 to 4 hours.

In one embodiment of the present invention, an extract was prepared by mixing lemon myrtle and zinnia mushroom at a weight ratio of 1:0.1 to 10, and as a result of analyzing the cytotoxicity of the extract according to the mixing ratio of lemon myrtle and zinnia mushroom, lemon myrtle and cauliflower mushroom mixed in a weight ratio of 1: 1 (Example 1), the mixed extract did not show cytotoxicity.

Therefore, in the present invention, the mixed extract may be obtained by mixing lemon myrtle and zinnia mushroom at a weight ratio of 1:0.1 to 10, and specifically, lemon myrtle and zinnia mushroom at a weight ratio of 1:0.5 to 5, preferably 1:1. It may be prepared by mixing and hot water extraction at 90 to 110 ° C.

In one embodiment of the present invention, it was confirmed that the DPPH scavenging activity increased in a concentration-dependent manner of the mixed extract of lemon myrtle and zinnia mushroom (Example 1, LB), and in order to analyze the antioxidant effect, brain inflammation was induced in mice with LPS As a result of analyzing the change in the production of lipid peroxide (MDA), an indicator of oxidative damage, by administration of the mixed extract (LB) of lemon myrtle and zinnia mushroom, LPS increased the amount of MDA production in the brains of experimental animals by 170%. . This means that oxidative damage was induced by LPS. It was confirmed that the high-dose administration (1000 mg/kg) of the mixed extract (LB) of lemon myrtle and zinnia mushroom statistically significantly reduced the amount of MDA produced by LPS.

That is, it was confirmed that the mixed extract of lemon myrtle and zinnia mushroom showed DPPH scavenging activity and had excellent antioxidant effect by inhibiting lipid peroxide (MDA) generated by oxidative damage. The extract can be used as an antioxidant composition.

In the present invention, "antioxidation" may be to protect cells from oxidative stress, specifically inhibiting the production of reactive oxygen species or lipid peroxide production.

In another embodiment of the present invention, in order to analyze the anti-inflammatory effect of the mixed extract (LB) of lemon myrtle and zinnia mushroom, brain inflammation was induced in mice with LPS, and then the mixed extract (LB) of lemon myrtle and zinnia mushroom was administered orally for 7 days. After administration, the degree of increase in microglia and astrocytes, which are inflammation-related cells, in brain tissue was analyzed. As a result of the analysis, LPS induced an increase in GFAP-positive cells, a marker for astrocytes, and Iba-1-positive cells, a marker for microglial cells, in the brains of experimental animals. It was confirmed that oral administration of the mixed extract (LB) of lemon myrtle and zinnia mushroom significantly reduced the increase in astrocytes (GFAP-positive cells) and microglial cells (Iba-1-positive cells) induced by LPS.

That is, it was confirmed that the mixed extract of lemon myrtle and zinnia mushroom exhibited an anti-inflammatory effect, and the mixed extract of lemon myrtle and zinnia mushroom of the present invention can be used as an anti-inflammatory composition.

In the present invention, "anti-inflammatory" is to inhibit or prevent the occurrence of inflammation, or to protect cells from damage caused by inflammation.

In the present invention, inflammation may be caused by microbial infection, exposure to yellow dust or fine dust, exposure to chemicals, or oxidative stress, but is not limited thereto.

The food composition of the present invention may include pills, powders, granules, infusions, tablets, capsules or liquids, etc., and there are no particular restrictions on the type of food to which the mixed extract of lemon myrtle and zinnia mushroom of the present invention can be added. There is no, for example, various beverages, gum, tea, vitamin complexes, health supplements, etc.

In addition to the mixed extract of lemon myrtle and zinnia mushroom, other ingredients may be added to the food composition, and the type is not particularly limited. For example, it may contain various herbal extracts, food additives or natural carbohydrates, etc., as additional components, as in conventional foods, but are not limited thereto.

In the present invention, "food supplement additive" refers to a component that can be added to food supplementally, and can be appropriately selected and used by those skilled in the art as being added to prepare health functional foods of each formulation. Examples of food additives include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners , pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc. are included, but the types of food additives of the present invention are not limited by the above examples.

Examples of the natural carbohydrate include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (thaumatin, etc.), stevia extract (rebaudioside A, glycir hijin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can advantageously be used.

There is no particular limitation on the type of food. Examples of foods to which the above substances can be added include meat, sausages, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice creams, various soups, beverages, tea, drinks, There are alcoholic beverages and vitamin complexes.

The food composition may be a health functional food composition.

In the present invention, "health functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functionality for the human body. Here, functional means obtaining useful effects for health purposes such as adjusting nutrients for the structure and function of the human body or physiological functions. The health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation. In addition, unlike general drugs, there is an advantage in that there is no side effect that may occur when taking a drug for a long time by using food as a raw material, and it can be excellent in portability.

The health functional food has the advantage of having a more excellent effect by ingesting it in the form of inner beauty food. The inner beauty refers to food referred to as 'eating cosmetics or beauty food', and refers to food that changes the skin constitution to be healthy by absorbing various ingredients good for the skin into the body. You can select and consume the inner beauty food that suits your individual skin condition and lifestyle. More preferably, when the cosmetics containing the mixed extract of lemon myrtle and zinnia mushroom and the inner beauty food containing the mixed extract of lemon myrtle and zinnia mushroom are mixed, the antioxidant or anti-inflammatory effect is superior to that of cosmetics alone. It has the advantage of being able to see more effective antioxidant or anti-inflammatory effects.

The mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment). In general, when preparing food, the mixed extract of lemon myrtle and zinnia mushroom of the present invention may be added in an amount of 1 to 50% by weight, preferably 5 to 10% by weight of the raw material composition, but is not limited thereto. . However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount below the above range may be used.

In another aspect, the present invention relates to a cosmetic composition for antioxidant or anti-inflammatory comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

Lemon myrtle, zinnia mushroom in the present invention. The description of the mixed extract, antioxidant and anti-inflammatory properties is as described above.

In addition to the mixed extract of lemon myrtle and zinnia mushroom, the cosmetic composition of the present invention may further include a compound or natural extract known to have antioxidant or anti-inflammatory effects so as to enhance or reinforce the antioxidant or anti-inflammatory effect.

In the cosmetic composition for antioxidant or anti-inflammatory use of the present invention, the active ingredient may be included in any amount (effective amount) according to the purpose of use, formulation, blending, etc., as long as it can exhibit antioxidant or anti-inflammatory effects. Based on the total weight, it may be included within the range of 0.001% by weight to 99.99% by weight. Here, "effective amount" refers to the amount of an active ingredient capable of inducing antioxidant or anti-inflammatory effects. Such an effective amount can be determined empirically within the ordinary skill of the skilled artisan.

The cosmetic composition of the present invention may be prepared in various forms, for example, the cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, a solution, suspension, paste, gel, cream , Lotion, powder, cleansing, oil, powder foundation, emulsion foundation, wax foundation and spray may be formulated, but is not limited thereto. In addition, specifically, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage cream, nutrient cream, moisture cream, hand cream, essence, nutrient essence, pack, soap, shampoo, It may have a formulation selected from the group consisting of cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, lipstick, makeup base, foundation, press powder, and loose powder, but is not limited thereto.

The cosmetic composition of the present invention may include a carrier acceptable in cosmetic formulations in addition to the active ingredient. Here, "acceptable carrier in cosmetic formulations" is a compound or composition that is already known and used that can be included in cosmetic formulations, or a compound or composition to be developed in the future, which does not have toxicity, instability, or irritation more than the human body can adapt to when in contact with the skin. say that The carrier may be included in the cosmetic composition of the present invention in an amount of about 1% to about 99.99% by weight, preferably about 5% to about 99% by weight, based on the total weight of the composition. However, since the ratio varies depending on the formulation of the cosmetic composition of the present invention and its specific application area (face or hand) or its preferred application amount, the ratio is intended to limit the scope of the present invention in any aspect. should not be understood

Meanwhile, as the carrier, alcohol, oil, surfactant, fatty acid, silicone oil, humectant, humectant, viscosity modifier, emulsion, stabilizer, sunscreen, coloring agent, fragrance, and the like may be exemplified. Alcohols, oils, surfactants, fatty acids, silicone oils, humectants, humectants, viscosity modifiers, emulsions, stabilizers, sunscreens, coloring agents, compounds/compositions that can be used as fragrances, etc. that can be used as the carrier are already known in the art. Therefore, those skilled in the art can select and use an appropriate material/composition.

In another aspect, the present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

In the present invention, lemon myrtle, zinnia mushroom, and a description of the mixed extract are as described above.

In the present invention, "inflammatory disease" is a disease caused by an inflammatory reaction (inflammation), the inflammation is induced by microbial (bacterial, viral, fungal) infection, yellow dust, fine dust, exposure to chemicals or oxidative stress It may be, but is not limited thereto.

The inflammatory disease is allergic disease, inflammatory bowel disease, atherosclerosis, inflammatory collagen blood vessel disease, glomerulonephritis, inflammatory skin disease, sarcoidosis, retinitis, gastritis, hepatitis, enteritis, arthritis, tonsillitis, sore throat, bronchitis, pneumonia, pancreatitis, It may be one selected from the group consisting of sepsis, brain or neuroinflammatory diseases, and nephritis.

In the above-described example of the present invention, it was confirmed that the mixed extract (LB) of lemon myrtle and zinnia mushroom suppressed the increase in the production of astrocytes and microglial cells, which are inflammation-related cells, in the brains of laboratory animals in which inflammation was induced by LPS. The mixed extract of bar, lemon myrtle and zinnia mushroom can be used to prevent or treat inflammatory diseases by suppressing inflammation.

In addition, it was confirmed that the mixed extract of lemon myrtle and zinnia mushroom inhibits inflammation of brain tissue, and in the present invention, the inflammatory disease may specifically be a brain or neuroinflammatory disease.

The brain or neuroinflammatory disease may be a degenerative brain disease caused by oxidative stress or excessive inflammatory response, and specifically, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. (ALS; Amyotrophic Lateral Sclerosis) may be one selected from the group consisting of.

In the present invention, "treatment" means reduction, suppression, sedation or eradication of an infectious disease or inflammatory disease, which is a target disease of the present invention. In the present invention, "prevention" means any action that inhibits or delays the onset of an infectious disease or inflammatory disease, which is the target disease of the present invention, and includes a therapeutic meaning.

The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount.

In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is subject type and severity, age, sex, disease type, drug activity, drug sensitivity, administration time, route of administration and excretion rate, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And it can be single or multiple administrations. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all the above factors, and can be easily determined by those skilled in the art.

The pharmaceutical composition of the present invention is not particularly limited as long as it is a subject for the purpose of treating or preventing an infectious disease or an inflammatory disease, and any one can be applied. For example, non-human animals such as monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cows, sheep, pigs, goats, and the like, humans, birds, and fish may be used, and the pharmaceutical composition may be administered parenterally or subcutaneously. , can be administered intraperitoneally, intrapulmonaryly and intranasally, and for local treatment, if necessary, by any suitable method including intralesional administration. The preferred dosage of the pharmaceutical composition of the present invention varies depending on the condition and body weight of the subject, the severity of the disease, the drug type, the route of administration and the period, but can be appropriately selected by those skilled in the art. For example, it may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection, but is not limited thereto.

The pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried agents, and suppositories. It may have a formulation, and may be of various oral or parenteral formulations. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, internal solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.

A suitable total daily amount can be determined by a treating physician within the scope of sound medical judgment, and is generally 0.001 to 1000 mg/kg, preferably 0.05 to 200 mg/kg, more preferably 0.1 to 100 mg/kg. The amount of kg can be divided and administered once a day to several times.

In another aspect, the present invention relates to a quasi-drug composition for antioxidant or anti-inflammatory comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

In the present invention, lemon myrtle, zinnia mushroom, mixed extract, antioxidant, and anti-inflammatory properties are as described above.

In the present invention, "quasi-drug" refers to items that have a milder action than pharmaceuticals among items used for the purpose of diagnosing, treating, improving, mitigating, treating or preventing diseases of humans or animals. For example, according to the Pharmaceutical Affairs Act, quasi-drugs are Textile/rubber products used for the treatment or prevention of human/animal diseases, non-tools or machines that have little or no direct action on the human body, and similar products that do not act directly on the human body, excluding items used for medicinal purposes; This includes disinfectants and insecticides to prevent it.

The type or formulation of the quasi-drug composition of the present invention is not particularly limited, but is preferably a disinfectant cleanser, shower foam, gargreen, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment, or filter filler.

When the composition of the present invention is included in a quasi-drug for antioxidant or anti-inflammatory purposes, the composition may be used as it is or used together with other quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined depending on the purpose of use, and the quasi-drug composition according to the present invention may contain the mixed extract of lemon myrtle and zinnia mushroom in an amount of 0.01 to 20% by weight based on the total weight of the composition.

In another aspect, the present invention relates to a cosmetic composition for anti-pollution comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.

In the present invention, descriptions of lemon myrtle, zinnia mushroom, mixed extract, and cosmetics are as described above.

In the present invention, “anti-pollution” means suppressing oxidative stress or inflammation induced by yellow dust or fine dust.

In the above-described examples of the present invention, it was confirmed that the mixed extract of lemon myrtle and zinnia mushroom had excellent DPPH radical scavenging activity, and it was confirmed that the antioxidant effect was excellent by suppressing the production of lipid peroxide induced by LPS in mice, It is possible to protect cells from yellow dust or fine dust by suppressing or reducing oxidative stress induced in cells by yellow dust or fine dust.

In addition, when inflammation was induced in brain tissue with LPS in mice to which the mixed extract of lemon myrtle and zinnia mushroom was orally administered, compared to the control group administered only with LPS, astrocytes (GFAP-positive cells) and microglial cells ( Iba-1 positive cells), the mixed extract of lemon myrtle and zinnia mushroom according to the present invention can protect cells by inhibiting or preventing inflammation induced by fine dust.

In addition, it was confirmed that oral administration of the mixed extract of lemon myrtle and zinnia mushroom suppressed inflammation in brain tissue, and the anti-pollution of the present invention specifically reduces the damage to nerves or brain cells caused by inflammation induced by fine dust. It may be to protect cells from damage.

Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.

1. Preparation of mixed extract of lemon myrtle and zinnia mushroom

After mixing dried lemon myrtle leaves and zinnia mushrooms in the weight ratio of Table 1, distilled water as a solvent was mixed and extracted for 3 hours using a pressurized extractor at 100 ° C, followed by filtration, concentration, and freeze-drying after freezing at -75 ° C deepfreezer. was used as

As a result of cytotoxicity analysis on the prepared mixed extract, Example 1 had no cytotoxicity.

sample name mixed amount lemon myrtle zinnia mushroom Example 1 (LB) 10g 10g Comparative Example 1 (L) 20g 0 Comparative Example 2 (B) 0 20g

2. In vitro ( In vitro ) Antioxidant effect analysis

1) DPPH radical scavenging activity assay

Samples prepared in Example 1 and Comparative Examples 1 and 2 were dissolved in distilled water to a concentration of 1000 μg/ml and used in experiments. DPPH (1,1-diphenyl-2-picrylhydrazyl) solution was prepared by mixing 3 ml of ethanol and 0.5 ml of DMSO with 1.5 ml of a solution of 3 mg of DPPH dissolved in 15 ml of ethanol.

DPPH radical scavenging activity was measured at 517 nm using a UV spectrophotometer for the concentration of residual radicals after mixing 50 μl of the sample and the DPPH solution and reacting at room temperature for 10 minutes.

DPPH radical scavenging activity was calculated by the electron donating ability (EDA %) as shown in Equation 1 below.

[Equation 1]

EDA(%)=(B-A)/B×100

A: absorbance of the sample-added group, B: absorbance of the sample-free group

division DPPH radical scavenging activity (EDA %) Example 1 (LB) 88.91 Comparative Example 1 (L) 67.59 Comparative Example 2 (B) 71.44

In order to measure the antioxidant effect of the mixed extract of lemon myrtle and zinnia mushroom (Example 1, LB), the DPPH radical scavenging ability (%) was analyzed in a test tube. The mixed extract of lemon myrtle and zinnia mushroom (Example 1, LB) It can be seen that shows superior DPPH scavenging activity than lemon myrtle (Comparative Example 1, L) or zinnia mushroom (Comparative Example 2, B) single extract.

3 In animal models ( In-vivo ) Analysis of antioxidant and anti-inflammatory effects

1) Preparation of experimental animals

Male ICR mice (6 weeks old) were purchased from Samtaco Bio and acclimatized for one week before use. The animals were reared in an individual breeding device with a temperature of 22 ± 1 °C and a humidity of 50 ± 10% with day/night cycles set at 12-hour cycles, and water and food were provided on an autonomous diet. The experimental groups were non-administration control group (sham), LPS control group (control), mixed extract (LB) of lemon myrtle and zinnia mushroom, and mixed extract of lemon myrtle and zinnia mushroom administered together with LPS. Low dose group (100LB, 100 mg/kg), mixed extract of lemon myrtle and zinnia mushroom (LB) high dose group (1000LB, 1000 mg/kg) group, lemon myrtle alone extract (L) and LPS administered together High-dose extract group (1000L, 1000 mg/kg), cauliflower mushroom alone extract (B) and LPS-administered cauliflower mushroom alone extract (B) high-dose group (1000B, 1000 mg/kg), and positive control group (ferulic acid, ferulic acid).

2) Drug (sample) administration and brain sample collection

The dosage of the mixed extract of lemon myrtle and cauliflower mushroom was set at a low dose (100LB, 100 mg/kg) and a high dose (1000LB, 1000 mg/kg), and the lemon myrtle alone extract (L) and cauliflower mushroom alone extract (B) were administered. The dose was set at a high dose (1000 mg/kg), and 20 mg/kg of ferulic acid used as a positive control was administered.

LPS was dissolved in PBS and administered at a dose of 1 μg/3 μl to the third ventricle. Each sample was dissolved in 10% tween 80 solution and orally administered 3 days before LPS administration.

Samples were orally administered for 7 days after LPS administration, and brain tissues of experimental animals were collected after 7 days. Half of the brain tissue was ground for western blot and ELISA analysis, and the other half was post-fixed for tissue immunostaining.

3) Antioxidant effect evaluation: Lipid peroxidation analysis (MDA measurement)

In order to analyze the antioxidant effects of the mixed extract of lemon myrtle and zinnia mushroom (LB), the single extract of lemon myrtle (L) and the single extract of zinnia zinnia (B), brain inflammation was induced in mice with LPS, and the effects of lemon myrtle and zinnia mushroom were analyzed. Changes in the production of lipid peroxide (MDA), an indicator of oxidative damage, by administration of the mixed extract (LB), lemon myrtle extract alone (L), and zinnia mushroom extract alone (B) were analyzed.

To measure changes in lipid peroxide, rat hippocampal tissue was homogenized at 4° C. using phosphate buffered saline (PBS). Then, the supernatant was used by centrifugation at 10,000 rpm for 5 minutes. Samples were treated with 0.15 M potassium chloride and 500 μl of each homogenized tissue, and 100 μl of 20 mM ferric chloride was added. Then, after reacting for 30 minutes in a 37° C. incubator, 500 μl of 0.25 N cold-HCl containing 15% TCA, 0.38% TBA and 0.5% BHT was added. After applying heat at 90 ° C. for 60 minutes, centrifugation was performed at 5,000 rpm and 4 ° C. for 5 minutes, and the absorbance of the supernatant was measured at a wavelength of 532 nm for thiobarbituric acid reactive substances (TBARS).

division MDA (% of control) No administration control group (sham) 100 LPS control 170 100 LB (100 mg/kg) 160 1000LB (100 mg/kg) 120 1000L (100 mg/kg) 140 1000 B (100 mg/kg) 135 Positive control (FA, 20 mg/kg) 115

As a result of the analysis, LPS increased the amount of MDA produced in the brains of experimental animals by 170%. This means that oxidative damage was induced by LPS. Statistically significant reduction in MDA production increased by LPS when high-dose administration (1000 mg/kg) of lemon myrtle and zinnia mushroom mixed extract (LB), lemon myrtle single extract (L) and zinnia mushroom single extract (B) It was confirmed that the mixed extract of lemon myrtle and zinnia mushroom (LB) statistically significantly reduced the amount of MDA production increased by LPS than the lemon myrtle single extract (L) and zinnia mushroom single extract (B). .

In addition, it was confirmed that ferulic acid (FA) used as a positive control also inhibited MDA production by LPS (Table 3).

4) Evaluation of anti-inflammatory effect: tissue immunostaining analysis of inflammatory cells

To analyze the anti-inflammatory effects of the mixed extract of lemon myrtle and zinnia mushroom (LB), the single extract of lemon myrtle (L), and the single extract of zinnia zinnia (B), brain inflammation was induced in mice with LPS, followed by 7 days of lemon myrtle and zinnia mushroom extract. Increased levels of inflammation-related cells, microglia and astrocytes, in brain tissue after oral administration of a mixed extract of cauliflower mushroom (LB), a single extract of lemon myrtle (L), and a single extract of cauliflower mushroom (B) was analyzed. Specifically, microglia using the Iba-1 antibody and astrocytes using the GFAP antibody were subjected to tissue immunostaining to analyze the degree of increase in each cell.

The hippocampus of the fixed brain tissue was picked, washed three times with PBS, and then treated with hydrogen peroxide to remove endogenous peroxidase. Thereafter, the primary antibody rabbit anti-Iba-1 (diluted 1:1000) or rabbit anti-GFAP (diluted 1:1000) was reacted overnight. As a secondary antibody, biotin and anti-rabbit (1:200 dilution) were used, followed by an ABC reaction, followed by color development using DAB for 3 minutes.

Three washes were done with PBS between each procedure. After completion of the staining reaction, the cover slide with the hippocampal tissue was covered with a mounting solution, dried, and stored. The brain tissue was mounted on a gelatin-coated slide, subjected to a process of 70 to 100% ethanol and xylene, and covered with a cover slide to store the tissue. Stained hippocampal slices were observed using an optical microscope (Olympus Microscope System BX51; Olympus, Tokyo, Japan). The area of each antibody-positive region was expressed as a ratio to the total area of the hippocampus.

division GFAP-positive area (%)
in the CA3 region No administration control group (sham) 0.021 LPS control 0.053 100 LB (100 mg/kg) 0.045 1000LB (100 mg/kg) 0.029 1000L (100 mg/kg) 0.038 1000 B (100 mg/kg) 0.041 Positive control (FA, 20 mg/kg) 0.027

division Iba-1-positive area (%)
in the CA3 region No administration control group (sham) 0.012 LPS control 0.059 100 LB (100 mg/kg) 0.039 1000LB (100mg/kg) 0.019 1000L (100 mg/kg) 0.034 1000 B (100 mg/kg) 0.037 Positive control (FA, 20 mg/kg) 0.017

As a result of the analysis, LPS induced an increase in GFAP-positive cells, a marker for astrocytes, and Iba-1-positive cells, a marker for microglial cells, in the brains of experimental animals. LPS-induced astrocytes (GFAP-positive cells) and microglial cells (Iba-1-positive cells) decreased, and the mixed extract of lemon myrtle and zinnia mushroom (LB) was more effective in LPS-induced astrocytes (GFAP-positive cells) and microglial cells than lemon myrtle alone extract (L) and zinnia mushroom alone extract (B). The increase in glial cells (Iba-1 positive cells) was reduced.

The positive control group (ferulic acid, FA) also inhibited the increase of astrocytes by LPS (Tables 4 and 5).

That is, it was confirmed that oral administration of the mixed extract (LB) of lemon myrtle and zinnia mushroom exhibited an anti-inflammatory effect in an animal model, and it was confirmed that the lemon myrtle alone extract (L) and the zinnia mushroom alone extract (B) had an anti-inflammatory effect. did

As such, it can be seen that the mixed extract of lemon myrtle and cauliflower mushroom according to the present invention has a synergistic effect superior to the case of using lemon myrtle or cauliflower mushroom alone.

Above, preferred embodiments of the present invention have been described in detail. The description of the present invention is for illustrative purposes, and those skilled in the art will understand that other specific forms can be easily modified without changing the technical spirit or essential features of the present invention.

Therefore, the scope of the present invention is indicated by the following claims rather than the detailed description, and all changes or modifications derived from the meaning, scope and equivalent concepts of the claims are interpreted as being included in the scope of the present invention. It should be.

Claims (9)

An antioxidant or anti-inflammatory food composition comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.
According to claim 1,
The mixed extract is an antioxidant or anti-inflammatory food composition extracted by mixing lemon myrtle and zinnia mushroom in a weight ratio of 1:0.1 to 10.
According to claim 1,
The mixed extract is a hot water extract of lemon myrtle and zinnia mushroom, antioxidant or anti-inflammatory food composition.
An antioxidant or anti-inflammatory cosmetic composition comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.
A pharmaceutical composition for the prevention or treatment of inflammatory diseases comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.
According to claim 5,
Wherein the inflammatory disease is a brain or neuroinflammatory disease, the pharmaceutical composition
An antioxidant or anti-inflammatory quasi-drug composition comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.
A cosmetic composition for anti-pollution comprising a mixed extract of lemon myrtle and zinnia mushroom as an active ingredient.
According to claim 8,
The anti-pollution is to suppress inflammation or oxidative stress induced by yellow dust or fine dust, anti-pollution food composition.